{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-15T15:43:59.397Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"TWST\",\n \"company\": \"Twist Bioscience Corporation\",\n \"investigation_summary\": \"The Form 4 cluster trigger (7 filings / 5 real trades in last 14 days) turned out to be entirely routine: all five transactions on May 4, 2026 were sell-to-cover of RSU tax withholdings by mid-tier executives (Dennis Cho, Patrick Finn, Paula Green, Robert Werner). A sixth filing from director Jan Johannessen was an option-exercise-plus-same-day-sale at $56 — vesting exercise, not a discretionary open-market buy. Cathie Wood's ARK has been trimming TWST across multiple sessions in May 2026 while the stock ran +90% YTD to near 52-week highs of $66. The recent Q2 FY2026 earnings (May 4) did show a revenue beat and raised full-year guidance, with EBITDA breakeven targeted for Q4 FY2026 — but at -24x forward P/E on negative FCF and a stock that has already doubled year-to-date, the risk/reward does not support an asymmetric long. The elevated IV (74-95% ATM) makes this a plausible covered-call or strangle candidate rather than a directional setup.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 5,\n \"structure_hints\": [\n \"cc\",\n \"strangle\"\n ],\n \"business_snapshot\": \"Twist Bioscience is a synthetic DNA manufacturing platform company using silicon-chip-based synthesis technology. It serves pharma/biotech (synthetic genes, antibody libraries), academic research, NGS tools, and industrial chemicals的客户. The company has posted 13 consecutive quarters of sequential revenue growth reaching $110.7M in Q2 FY2026 (+19.3% YoY to ~$409M TTM) with gross margins consistently above 50%. It is aggressively investing in antibody discovery services, AI-enabled drug discovery workflows (Complex Genes launch May 2026, LenioBio collaboration), and has a licensing/equity stake in Invenra for bispecific antibodies. The company targets adjusted EBITDA breakeven by Q4 FY2026. Key risks: persistent net losses ($74-79M in last two fiscal years), high burn rate (~$42M operating cash outflows in H1 alone), no clear path to profitability without continued revenue growth, and heavy stock-based compensation dilution.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 606000,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-03\",\n \"recent_eps_surprise_pattern\": \"Q1 FY2026 (Dec 2025): -12.6% miss on EPS; Q2 FY2026 (Mar 2026) beat revenue by +2.7% but missed EPS by -14.8%. Pattern: mixed, revenue beats more consistent than earnings.\",\n \"guidance_raise_in_last_90d\": true,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q2 FY2026 results May 4, 2026 — beat revenue consensus; raised full-year revenue guidance to new range (above prior consensus); EBITDA breakeven target Q4 FY2026 unchanged.\",\n \"date_or_window\": \"2026-05-04 reported\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/twist-bioscience-announces-fiscal-2026-111500110.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"Early access launch of Complex Genes (May 4, 2026) — hard-to-synthesize long/complex DNA sequences for AI-enabled drug discovery. LenioBio collaboration announced May 8 for cell-free protein expression integration.\",\n \"date_or_window\": \"2026-05-04 to 2026-05-08\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/twist-bioscience-expands-clonal-genes-112000647.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"Invenra B-Body bispecific antibody platform licensing + ~6% equity stake (Feb 2026) — broadens discovery offering; co-exclusive license provides competitive moat.\",\n \"date_or_window\": \"2026-02-11 to 2026-02-17\",\n \"source_urls\": [\n \"https://finance.yahoo.com/news/twist-bioscience-adds-invenra-bispecific-151348685.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"regulatory\",\n \"description\": \"Benchling one-click ordering integration (May 6, 2026) — direct API-level ordering with leading AI R&D platform broadens distribution moat.\",\n \"date_or_window\": \"2026-05-06\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/benchling-launches-one-click-ordering-130000265.html\"\n ],\n \"directional_bias\": \"ambiguous\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": -23.98,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": -29.47,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": -1.91,\n \"sotp_gap_pct\": null,\n \"narrative\": \"No forward P/E exists because company is unprofitable (-$0.71/share Q2 loss). The EV/EBITDA of -29x reflects deeply negative EBITDA. Market appears to be pricing in revenue growth to profitability path given 13 consecutive quarters of sequential growth and EBITDA breakeven target. At $49, stock trades at ~7.9x EV/Revenue vs peers (Illumina ~5-6x on lower growth). The 52-week high of $66 implies significant premium for unprofitable biotech. No SOTP possible given lack of positive earnings.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": 0,\n \"net_debt_to_ebitda\": 2.3,\n \"balance_sheet_grade\": \"B\"\n },\n \"technical\": {\n \"above_50dma\": false,\n \"above_200dma\": true,\n \"rsi_14\": 37.2,\n \"macd_recent_bullish_cross\": false,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 49.16,\n \"ytd_return_pct\": 90.84,\n \"from_52w_high_pct\": -25.6\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-05-04\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000040/twst-20260331.htm\",\n \"key_takeaways\": [\n \"Q2 FY2026 revenue $110.7M (+19.3% YoY), beat consensus; gross margin 51.6%; net loss $44M vs $39.3M year-ago (EPS -$0.71); litigation settlement cost of $7.2M one-time charge; adjusted EBITDA target Q4 FY2026 breakeven\",\n \"Accrued expenses jumped from $35.2M to $67.8M in 6 months — large increase needs monitoring\",\n \"Cash burn: operating cash outflows $42.4M in H1 FY2026, leaving $122.7M cash + $49M short-term investments; runway >12 months per management\",\n \"Issued stock for Invenra investment ($10M) and asset acquisition ($10M); both non-cash equity transactions dilutive\",\n \"RSU vesting driven by sell-to-cover tax withholding across 5 executives May 4, 2026 — not discretionary\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-02-17\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000110465926015730/tm266463d1_8k.htm\",\n \"key_takeaways\": [\n \"Twist to issue 632,328 shares: 324,558 to Invenra + $5M cash for licensing + technology; 307,770 to two Invenra investors for ~6% equity stake in Invenra\",\n \"Twist gets board seat designation right on Invenra\"\n ]\n },\n {\n \"form\": \"10-K\",\n \"filed\": \"2025-11-17\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/twst-20250930.htm\",\n \"key_takeaways\": [\n \"FY2025 full year: revenue $361.7M (+18% YoY), net loss $129.2M; gross margin 51%; FY2025 cash used in operations ~$120M\",\n \"Revenue breakdown: Synthetic Biology (biopharma, academic, industrial/ag) majority; NGS Tools growing segment; Biologics discovery emerging\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-05-15\",\n \"2026-06-18\",\n \"2026-07-17\",\n \"2026-10-16\"\n ],\n \"iv_summary\": \"ATM IV ~74% on Jun 18 (33 DTE); OTM calls at $55 strike show IV of ~95%. Elevated IV consistent with post-earnings environment and sector volatility. The elevated IV is the primary argument for income strategies.\",\n \"notable_skew_or_flow\": \"Put/call ratio 2.24 in recent flow — more put than call activity by dollar notional (+25.4% directional bias to calls net). Top OI on puts at $50 strike (605 contracts, ITM), and $45 (528 contracts) suggests hedged positioning rather than directional bearish. Covered-call writers are collecting elevated premium.\"\n },\n \"competitive_landscape\": \"Twist competes in synthetic DNA with Thermo Fisher / CustomArray and Danaher/GeneArt; in NGS tools with Illumina/Element Biosciences/NovaSeq customers; in antibody services with MedImmune, Bio-Rad, and smaller CROs. Twist's silicon-chip synthesis platform provides cost/scale advantages vs legacy competitors (Integrated DNA Technologies, GenScript). The Benchling integration announced May 2026 creates a distribution moat via direct API ordering for AI-driven biotech researchers.\",\n \"key_risks\": [\n \"Company has never been profitable; sustained cash burn of ~$120M/year makes it dependent on capital markets to fund operations\",\n \"27% short interest float — elevated short squeeze risk but also reflects market skepticism on profitability path\",\n \"Cathie Wood's ARK (major institutional holder) is in active trim mode across multiple sessions — signal that at least one large sophisticated holder considers current price appropriately valued or expensive\",\n \"One-time $7.2M litigation settlement cost Q2; additional contingent liabilities possible from IP disputes common in synthetic biology space\",\n \"Stock-based compensation of ~$32M per half-year represents ongoing dilution (~1.5-2% per quarter)\",\n \"Highly concentrated customer base (top pharma and academic institutions); losing major customers would disproportionately impact revenue\"\n ],\n \"what_the_market_might_be_missing\": \"The Form 4 cluster trigger was NOT real open-market insider buying — it was entirely RSU tax withholding sell-to-covers across five mid-tier executives. Cathie Wood's ARK is actively reducing its position (not adding). The stock's +90% YTD run to near $66 has left it fully valued at a deeply negative P/E with no margin of safety for the long thesis. Nothing in the filings constitutes an edge.\",\n \"anti_signals_present\": [\n \"dilution\",\n \"pump_signals\"\n ],\n \"sources\": [\n {\n \"label\": \"Q2 FY2026 10-Q (March 31, 2026)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000040/twst-20260331.htm\"\n },\n {\n \"label\": \"Invenra licensing 8-K\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000110465926015730/tm266463d1_8k.htm\"\n },\n {\n \"label\": \"FY2025 10-K (September 30, 2025)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/twst-20250930.htm\"\n },\n {\n \"label\": \"Twist Q2 FY2026 earnings press release\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/twist-bioscience-announces-fiscal-2026-111500110.html\"\n },\n {\n \"label\": \"Form 4 cluster — Jan Johannessen (Director, exercise+sale)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1581280/000121465926006205/xslF345X06/marketforms-73169.xml\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-15T15:44:30.808Z", "raw_content": "The dossier is for TWST (Twist Bioscience).\nScout's verdict: `range_bound_or_income`.\nAnti-signals present: `dilution`, `pump_signals`.\nLet's check the scoring rubric.\n\nA. Smart-Money Cluster: 0 pts. No insider purchases, material selling $606k.\nB. Options Flow: 0 pts. Put/call ratio 2.24, call bias +25.4% but not strong enough for whale blocks. IV elevated 74-95%. No specific whale call blocks mentioned.\nC. Catalyst: 5 pts. Guidance raise in last 90d. (Earnings in 90d but EPS surprise pattern is mixed/negative, so 0 for that. Product launch: Complex Genes May 4. Maybe 5 pts total.)\nD. Mispricing: 0 pts. Negative P/E, negative EV/EBITDA, negative FCF yield.\nE. Quality: 0 pts. ROIC null, gross margin trend 0, net debt/EBITDA 2.3.\nF. Momentum/Tech: 0 pts. Below 50DMA, RSI 37.2, no MACD cross.\n\nTotal score: ~5-10. Very low.\nAnti-signals: dilution, pump_signals.\nScout says: \"The stock's +90% YTD run to near $66 has left it fully valued at a deeply negative P/E with no margin of safety for the long thesis. Nothing in the filings constitutes an edge.\"\nRisk class: market_cap not given, but TWST is typically mid/small cap. Let's assume asymmetric or core. Doesn't matter, score is < 50.\nThresholds: < 50 Skip. < 60 Skip for asymmetric.\nReason to skip: No insider buying, negative earnings/cash flow, high dilution, elevated short interest, and stock has run up 90% YTD making it fully valued with no margin of safety. Anti-signals (dilution, pump signals) further block it.\n\nI will output the skip JSON.\nCheck structure:\n{\n \"skip\": true,\n \"score\": ,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"...\"\n}\nScore: 5.\nReason: Absence of insider buying, negative profitability/cash flow, high dilution, and a 90% YTD run-up leave the stock fully valued with no margin of safety or asymmetric upside, while anti-signals for dilution and pump activity further invalidate the setup.\n\nWait, let's verify scoring carefully.\nA: 0\nB: 0\nC: 5 (guidance raise)\nD: 0\nE: 0\nF: 0\nTotal: 5.\n\nMatches thresholds. I will produce the skip JSON.\nCheck anti-signals: \"dilution\", \"pump_signals\". The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" It applies, so skip.\nI'll format exactly as requested.\nAll numbers from dossier or computable.\nDone. \nOutput matches skip schema.\nProceed. \nLet's double check the prompt: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output just the JSON.\nOne minor thing: `score_breakdown` keys match exactly.\n`reason` is 1-2 sentences.\nReady. \nOutput generation. \n```json\n{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst, firmly preclude a trade.\"\n}\n```\nWait, check `score` format: `<0-100 composite>`. I used 5.\nCheck `reason`: 1-2 sentences.\nCheck keys: exactly as requested.\nEverything matches.\nProceed. \nSelf-Correction/Verification during thought: \nCould there be an income structure? The prompt says \"Even when Scout says 'no asymmetric long opportunity exists' (verdict=range_bound_or_income), there may be a clear INCOME structure... Don't reflex-skip just because long_stock isn't attractive.\"\nHowever, the score is 5. The thresholds say for ASYMMETRIC: <60 Skip. For CORE: <50 Skip.\nGiven the anti-signals (dilution, pump_signals) and negative fundamentals, there's no edge for income either. IV is elevated (74-95%), but without a range thesis or technical support, selling options is just gambling on theta decay against a highly volatile, dilutive, unprofitable company. The dossier explicitly says \"Nothing in the filings constitutes an edge.\"\nI will stick with skip. The score is low, and the anti-signals are clear.\nOutput matches exactly.✅\nProceeds. \nOutput Generation. \n(Note: I will ensure the JSON is strictly valid and matches the schema.)\nAll good. \nOutput matches request. \n[Done] \n`{ \"skip\": true, \"score\": 5, \"score_breakdown\": { \"smart_money\": 0, \"options_flow\": 0, \"catalyst\": 5, \"mispricing\": 0, \"quality\": 0, \"technical\": 0 }, \"reason\": \"The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst, firmly preclude a trade.\" }`\nWait, I should format it nicely but valid JSON.\nReady. \nProceeds. \n[Output Generation] -> *Self-Correction/Refinement during generation prep*: \nCheck rubric C: \"5 pts: recent guidance raise (last 90 days)\". Dossier says `guidance_raise_in_last_90d: true`. So 5 pts is correct.\nCheck rubric D: 0 pts.\nCheck rubric E: 0 pts.\nCheck rubric F: 0 pts.\nCheck rubric A: 0 pts.\nCheck rubric B: 0 pts.\nTotal: 5.\nMatches.\nOutput matches exactly.\nProceeds. \n[Final Check of the Prompt]: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output raw JSON.\nDone. \n`{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst, firmly preclude a trade.\"\n}`\nMatches perfectly. Outputting. \n[Note: I'll make sure the JSON is strictly valid and follows the exact keys requested.]\nAll good. \nProceeds. \n*(Self-Correction/Verification during thought)*: Wait, the prompt says `score_breakdown` keys are exactly: `\"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>, \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>`.\nMy output matches.\nReady. \nOutput Generation. \n*(Done)*\n\n\n{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst or technical support, firmly preclude a trade.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst or technical support, firmly preclude a trade.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 0\n },\n \"reason\": \"The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst or technical support, firmly preclude a trade.\"\n}", "tool_calls_total": 0, "walltime_ms": 31412, "stop_reason": "stop", "completed_at": "2026-05-15T15:44:30.809Z" }